{"id":380699,"date":"2020-11-13T07:20:24","date_gmt":"2020-11-13T12:20:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380699"},"modified":"2020-11-13T07:20:24","modified_gmt":"2020-11-13T12:20:24","slug":"appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/","title":{"rendered":"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021<\/b><\/p>\n<p>HALIFAX, Nova Scotia&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAppili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2021, which ended September 30, 2020.\n<\/p>\n<p>\n\u200bSecond quarter and recent operational highlights include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FAppili-Therapeutics-Joins-Dr.-Reddy%25E2%2580%2599s%252C-Global-Response-Aid%252C-and-FUJIFILM-in-Advancing-Avigan%25C2%25AE-Tablets-for-the-Potential-Treatment-of-COVID-19&amp;esheet=52326604&amp;newsitemid=20201113005159&amp;lan=en-US&amp;anchor=Entering+into+a+global+partnership+agreement&amp;index=1&amp;md5=4062d8234542371afcf2b2a69fd07c93\">Entering into a global partnership agreement<\/a> with Dr. Reddy\u2019s Laboratories Ltd., Global Response Aid, and FUJIFILM Toyama Chemical Co. for the worldwide development and distribution of Avigan<sup>\u00ae<\/sup> tablets (favipiravir) for the potential prevention and treatment of COVID-19 (excluding Japan, China, and Russia)\n<\/li>\n<li><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FAppili-Submits-Protocol-for-a-Phase-3-Study-Evaluating-Favipiravir-for-the-Treatment-of-Patients-with-COVID-19-Infections-to-the-US-FDA-&amp;esheet=52326604&amp;newsitemid=20201113005159&amp;lan=en-US&amp;anchor=Filing+a+protocol+with+the+U.S.+Food+and+Drug+Administration+%28FDA%29&amp;index=2&amp;md5=46d6316ce026109fff854f4f04bbaa1c\">Filing a protocol with the U.S. Food and Drug Administration (FDA)<\/a> for the Company\u2019s Phase 3 trial evaluating Avigan\u00ae as a potential treatment for COVID-19 in the U.S.\n<\/li>\n<li><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FFirst-Participants-Dosed-in-Appili-Therapeutics%25E2%2580%2599-Phase-2-Clinical-Trial-Evaluating-Favipiravir-for-COVID-19-Outbreak-Control-in-Canadian-Long-Term-Care-Homes&amp;esheet=52326604&amp;newsitemid=20201113005159&amp;lan=en-US&amp;anchor=Enrolling+and+dosing+the+first+cluster+of+participants&amp;index=3&amp;md5=1c3c635242f7838724e4da957b4534cd\">Enrolling and dosing the first cluster of participants<\/a> in our CONTROL Phase 2 trial evaluating Avigan<sup>\u00ae<\/sup> for outbreak control against COVID-19 in Canadian long-term care facilities\n<\/li>\n<li><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FAppili-Therapeutics-Appoints-Drug-Development-Executive-Don-Cilla-to-the-Newly-Created-Position-of-Chief-Development-Officer&amp;esheet=52326604&amp;newsitemid=20201113005159&amp;lan=en-US&amp;anchor=Appointing+senior+drug+development+executive+Don+Cilla&amp;index=4&amp;md5=cbd5e5f9fcbc22759bbf3bb4ee1c46ea\">Appointing senior drug development executive Don Cilla<\/a> to serve as Appili\u2019s Chief Development Officer\n<\/li>\n<li>\nGraduating to the main board of the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FAppili-Therapeutics-to-Commence-Trading-on-Main-Board-of-the-TSX-Exchange-&amp;esheet=52326604&amp;newsitemid=20201113005159&amp;lan=en-US&amp;anchor=Toronto+Stock+Exchange+%28TSX%29&amp;index=5&amp;md5=c348b8af1a7924c834dca61bba0c60a8\">Toronto Stock Exchange (TSX)<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FAppili-Therapeutics-Receives-Eligibility-for-DTC-Trading-in-the-U.S&amp;esheet=52326604&amp;newsitemid=20201113005159&amp;lan=en-US&amp;anchor=earning+DTC+eligibility&amp;index=6&amp;md5=e06924b0fa364f6bda9c703bb57b5d2a\">earning DTC eligibility<\/a> in the U.S.\n<\/li>\n<\/ul>\n<p>\n\u201cAs the world enters the next wave of COVID-19 infections, our antiviral programs are steadily advancing. We were very pleased to sign a global deal with world-class partners to develop Avigan<sup>\u00ae<\/sup> for the potential treatment and prevention of COVID-19, to dose the first participants in our CONTROL trial, and to file a protocol with the U.S. FDA for Appili\u2019s first Phase 3 study, which is investigating Avigan\u00ae for the treatment of early-to-moderate COVID-19 infections,\u201d said<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fleadership&amp;esheet=52326604&amp;newsitemid=20201113005159&amp;lan=en-US&amp;anchor=Kimberly+Stephens%2C+Chief+Financial+Officer+of+Appili+Therapeutics.&amp;index=7&amp;md5=526bffe837c82da3e1bad58c0d47f9df\"> Kimberly Stephens, Chief Financial Officer of Appili Therapeutics.<\/a> \u201cWe\u2019ve also staffed key positions, including the appointment of Don Cilla as Chief Development Officer, and graduated to the TSX exchange within 18 months of originally listing on the TSX Venture Exchange. We continue to work diligently to progress our clinical programs, bolster our financial position, expand our team, and drive value for our pipeline portfolio.\u201d\n<\/p>\n<p><b>Financial Results<\/b><\/p>\n<p>\nThe Company prepares its financial statements in accordance with IFRS as issued by the International Accounting Standard Board and Part I of Chartered Professional Accountants of Canada Handbook \u2013Accounting. All dollar figures are $CAN unless otherwise noted.\n<\/p>\n<p>\nThe net loss and comprehensive loss of $5.1 million or $0.09 loss per share for the six months ended September 30, 2020 was $2.1 million higher than the net loss and comprehensive loss of $2.9 million or $0.09 loss per share during the six months ended September 30, 2019. This relates mainly to a $1.6 million increase in research and development (R&amp;D) expenses, a $0.8 million increase in general and administrative expenses, offset by a $0.3 million decrease in business development expenses.\n<\/p>\n<p>\nAs of September 30, 2020, the Company had cash and short-term investments of $22.9 million, compared to $10.5 million on March 31, 2020. As of November 12, 2020, the Company 62,284,216 issued and outstanding Common Shares, 4,548,949 stock options and 15,011,610 warrants outstanding.\n<\/p>\n<p>\nThis press release should be read in conjunction with the Company\u2019s unaudited interim condensed financial statements for September 30, 2020 and the related management discussion and analysis (MD&amp;A), copies of which are available on SEDAR at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedar.com%2F&amp;esheet=52326604&amp;newsitemid=20201113005159&amp;lan=en-US&amp;anchor=www.sedar.com&amp;index=8&amp;md5=6230d80f7b25e21e9e5eaad51490d2ce\">www.sedar.com<\/a>.\n<\/p>\n<p><b>About Appili Therapeutics<\/b><\/p>\n<p>\nAppili Therapeutics Inc. was founded to advance the global fight against infectious disease by matching clearly defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this critical disease space. Appili has built a pipeline of assets designed to address a broad range of significant unmet medical needs in the infectious disease landscape. Appili\u2019s diverse pipeline aims to address some of the most urgent threats in global public health, including Avigan\u00ae tablets, which Appili is evaluating, as part of a consortium with Dr. Reddys Labs, Global Response Aid, and FujiFilm Toyama Chemical for the global treatment and prevention of COVID-19. Appili is also evaluating ATI-2307, a novel, broad spectrum, clinical-stage antifungal candidate in development for severe and difficult-to-treat invasive fungal infections; ATI-1701, a vaccine candidate for tularemia, a very serious biological weapons threat; ATI-1503, a drug discovery program aimed at generating a novel class of antibiotics with broad-spectrum activity against Gram-negative superbugs; and ATI-1501, which employs Appili\u2019s proprietary, taste-masked, oral-suspension technology with metronidazole for the growing number of patients with difficulty swallowing. In addition, Headquartered in Halifax, Nova Scotia, with offices in Toronto, Ontario, Appili is pursuing worldwide opportunities in collaboration with scientific and industry commercial partners, governments and government agencies. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.AppiliTherapeutics.com&amp;esheet=52326604&amp;newsitemid=20201113005159&amp;lan=en-US&amp;anchor=www.AppiliTherapeutics.com&amp;index=9&amp;md5=b1c356c4e3a337ce1a634cfa46fa517a\">www.AppiliTherapeutics.com<\/a>.\n<\/p>\n<p><i>This news release contains \u201cforward-looking statements\u201d which reflect the current expectations of the Company\u2019s management future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as \u201cmay,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cplan,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201cpotential for,\u201d and similar expressions have been used to identify these forward-looking statements. Forward-looking statements involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in the annual information form of the Company dated June 24, 2020 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedar.com&amp;esheet=52326604&amp;newsitemid=20201113005159&amp;lan=en-US&amp;anchor=www.sedar.com&amp;index=10&amp;md5=add01d2d11e2c87bcc6073b79b03ec00\">www.sedar.com<\/a>). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201113005159r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201113005159\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201113005159\/en\/<\/a><\/span><\/p>\n<p><b><i>Media Contact<\/i><\/b>:<br \/>\n<br \/>Andrea Cohen<br \/>\n<br \/>Sam Brown Inc.<br \/>\n<br \/>T: 917-209-7163<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:andreacohen@sambrown.com\">andreacohen@sambrown.com<\/a><\/p>\n<p><b><i>Investor Relations Contact<\/i><\/b>:<br \/>\n<br \/>Kimberly Stephens, CFO<br \/>\n<br \/>Appili Therapeutics<br \/>\n<br \/>TSX: APLI<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:Info@AppiliTherapeutics.com\">Info@AppiliTherapeutics.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Other Science Biotechnology Research Pharmaceutical Health Infectious Diseases Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201113005159\/en\/838652\/3\/AppiliLogo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021 HALIFAX, Nova Scotia&#8211;(BUSINESS WIRE)&#8211; Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2021, which ended September 30, 2020. \u200bSecond quarter and recent operational highlights include: Entering into a global partnership agreement with Dr. Reddy\u2019s Laboratories Ltd., Global Response Aid, and FUJIFILM Toyama Chemical Co. for the worldwide development and distribution of Avigan\u00ae tablets (favipiravir) for the potential prevention and treatment of COVID-19 (excluding Japan, China, and Russia) Filing a protocol with the U.S. Food and Drug Administration (FDA) for the Company\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380699","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021 HALIFAX, Nova Scotia&#8211;(BUSINESS WIRE)&#8211; Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2021, which ended September 30, 2020. \u200bSecond quarter and recent operational highlights include: Entering into a global partnership agreement with Dr. Reddy\u2019s Laboratories Ltd., Global Response Aid, and FUJIFILM Toyama Chemical Co. for the worldwide development and distribution of Avigan\u00ae tablets (favipiravir) for the potential prevention and treatment of COVID-19 (excluding Japan, China, and Russia) Filing a protocol with the U.S. Food and Drug Administration (FDA) for the Company\u2019s &hellip; Continue reading &quot;Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T12:20:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201113005159r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021\",\"datePublished\":\"2020-11-13T12:20:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/\"},\"wordCount\":1002,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201113005159r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/\",\"name\":\"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201113005159r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-11-13T12:20:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201113005159r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201113005159r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/","og_locale":"en_US","og_type":"article","og_title":"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021 - Market Newsdesk","og_description":"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021 HALIFAX, Nova Scotia&#8211;(BUSINESS WIRE)&#8211; Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2021, which ended September 30, 2020. \u200bSecond quarter and recent operational highlights include: Entering into a global partnership agreement with Dr. Reddy\u2019s Laboratories Ltd., Global Response Aid, and FUJIFILM Toyama Chemical Co. for the worldwide development and distribution of Avigan\u00ae tablets (favipiravir) for the potential prevention and treatment of COVID-19 (excluding Japan, China, and Russia) Filing a protocol with the U.S. Food and Drug Administration (FDA) for the Company\u2019s &hellip; Continue reading \"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T12:20:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201113005159r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021","datePublished":"2020-11-13T12:20:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/"},"wordCount":1002,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201113005159r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/","name":"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201113005159r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-11-13T12:20:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201113005159r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201113005159r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-second-quarter-of-fiscal-year-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380699"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380699\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}